Submissions

Allergy & Anaphylaxis Australia (A&AA) is a charitable, non-profit organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals and their families to enjoy an optimal quality of life whilst minimising risk to their health and wellbeing. A&AA strives to raise awareness of allergy in the community and provides evidence-based information, resources and services to support children and adults living with allergic disease including food allergy. 

Select a link below to access A&AA's submission.

Submission concerning Jorveza® for EoE change to current PBS listing - 23 Jan 2023

Submission from Allergy & Anaphylaxis Australia (A&AA): We welcome the opportunity to lodge our comments in support of the submission for Jorveza® (Budesonide) which is on the March 2023 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jorveza® was PBS listed in May 2022 specifically for the treatment of EoE. This application is for...

Continue reading

Submission on change to PBS listing Mepolizumab Injection - 15 Sep 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Change to PBS listing Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA supports the PBS listing of Mepolizumab so that people with chronic rhinosinusitis with nasal polyps can, together with their treating medical...

Continue reading

Submission concerning Codex Committee on Food Labelling | Response - 8 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Committee on Food Labelling | Electronic Working Group on Allergen Labelling.  A&AA provides response on 1st Consultation Paper on the Codex eWG Allergen Labelling online-forum. Response form A&AA to Codex Committee on Food Labelling 8 July 2022195.71 KB    

Continue reading

Submission concerning Codex Contact Point - 7 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Contact Point for Australia Secretariat A&AA appreciates the opportunity to provide feedback to the Codex Contact Point for Australia Secretariat on food information requirements for pre-packaged foods offered via e-commerce. Submission concerning Codex Contact Point - 7 July 2022224.86...

Continue reading

FSANZ submission: P1028 - Infant formula -14 June 2022

Allergy & Anaphylaxis Australia lodged a further submission with Food Standards Australia New Zealand (FSANZ) with regard to P1028 - Infant formula. A&AA supports the creation of a new category Special Medical Purpose Products for infants (SMPPi) within Standard 2.9.1, and supports the proposed labelling requirements for inner packages, preferably...

Continue reading

Submission concerning Dupixent for severe eczema - 16 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA):Dupixent for severe eczema.  A&AA asks that you consider the changed lives of people with severe eczema who are now taking Dupixent in the July 2022 PBAC meeting. People are utilising the medication because there has been a huge need for a treatment that works without the need for immunosuppressive...

Continue reading

Submission concerning Review of the WA Food Act - 3 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Review of the WA Food Act.  A&AA has no issue with the efficacy of the current provisions in the WA Food Act, noting that they appear in line with the Model Food Provisions. A&AA strongly urges the addition of provisions in the WA Food Act to address food allergy management throughout...

Continue reading

Submission concerning Food allergen content exemptions - 30 April 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Food allergen content exemptions cannot be considered because there is a huge food safety risk to consumers with food allergy. This will impact greatly on the health and wellbeing of people with food allergy and potentially add more of a challenge to an existing crisis such as Covid-19/natural disasters....

Continue reading

Submission concerning Proposal P1053: Food safety management tools - 6 April 2022

Allergy & Anaphylaxis Australia lodged a submission with Food Standards Australia New Zealand Food Standards Australia New Zealand (FSANZ) concerning Proposal P1053: Food safety management tools for the food service and closely related retail sectors. Submission from Allergy & Anaphylaxis Australia: Proposal P1053: Food safety management tools231.59...

Continue reading

Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022

Allergy & Anaphylaxis Australia lodged a submission with Codex Australia concerning the proposed Guidelines on the Use of Technology to Provide Food Information. A&AA Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022332.58 KB  

Continue reading

PBAC Submission support for listing of Dupilumab (Dupixent®) on the PBS - 20 January 2022

Allergy & Anaphylaxis Australia lodged a submission with Pharmaceutical Benefits Advisory Committee (PBAC) supporting the Pharmaceutical Benefits Scheme (PBS) listing of Dupilumab (Dupixent®) for the treatment of severe atopic dermatitis (commonly known as eczema) in children aged 6 to 11 years. A&AA PBAC Submission for listing of Dupilumab (Dupixent®)...

Continue reading

Food Standards Australia New Zealand (FSANZ) submission: P1028 - Infant formula - 20 Oct 2021

Allergy & Anaphylaxis Australia lodged a submission with Food Standards Australia New Zealand (FSANZ) with regard to P1028 - Infant formula. With respect to the management of food allergy, A&AA has had access to the draft submissions of both the NAS and ASCIA and supports and endorses their submissions. A&AA FSANZ submission: P1028 - Infant formula...

Continue reading

Review of National Medicines Policy - Allergy and Anaphylaxis Australia submission - 8 Oct 2021

Allergy & Anaphylaxis Australia (A&AA) lodged a submission to the Review of National Medicines Policy.  Included were submisions on: Terms of Reference 1: Evaluate the current NMP objectives and determine whether these should be modified or additional objectives included. This includes consideration of the proposed Principles to be included...

Continue reading

PBAC Budesonide (Jorveza®) submission for use in EoE (Eosinophilic Oesoghagitis) - 22 Sep 2021

Allergy & Anaphylaxis Australia lodged comments in support of the application for Pharmaceutical Benefits Scheme (PBS) listing of JORVEZA® for both induction of remission and maintenance of remission in adult patients with Eosinophilic Oesophagitis (EoE). A&AA PBAC Budesonide (Jorveza®) submission for use in EoE (Eosinophilic Oesoghagitis) - 22 Sep 2021175.93...

Continue reading

Mepolizumab Injection (Nucala®) to include use for chronic rhinosinusitis with nasal polyps - 17 Sep 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on change ot Pharmaceutical Benefits Scheme listing of Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA Mepolizumab Injection (Nucala) change of PBS listing Sep 2021179.29...

Continue reading

ABROCITINIB Cibinqo® submission supporting PBS Listing for severe atopic dermatitis - 13 Sep 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of ABROCITINIB Tablet 100 mg Tablet 200 mg Cibinqo® for severe atopic dermatitis. A&AA Abrocitinib Submission Sep 2021179.99 KB  

Continue reading

Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD). A&AA Upadacitinib Rinvoq Submission May 2021183.25 KB  

Continue reading

Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021

Allergy & Anaphylaxis Australia made a submission to to Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme (PBAC) listing of Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD). A&AA Baricitinib Olumiant Submission May 2021167.27 KB

Continue reading

Building a more robust medicine supply: Proposals -16 May 2021

Allergy & Anaphylaxis Australia (A&AA) made a submission to Therapeutic Good Administrations (TGA) on Building a more robust medicine supply - Proposals to help prevent, mitigate and manage medicine shortages with the following proposals:  Proposal 1 – Prioritising evaluation of important generic medicines Proposal 3 – Improving reliability of supply...

Continue reading

General Standard for the Labelling of Pre-packaged Foods (CXS 1 1985) - 2 Mar 2021

Allergy & Anaphylaxis Australia (A&AA) made a submission with regard to Request for comments / information on allergen labelling: revision of the General Standard for the Labelling of Pre-packaged Foods (CXS 1 1985) (For further information please see CL 2021/9/OCS-FL). CONSULTATION QUESTIONS Question 1 Does the scope of the GSLPF need clarifying...

Continue reading

More Articles ...

  • 1
  • 2

Food Alerts

More Food Alerts

Latest News

More Latest News
Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond

Viatris
Sanofi
Nestle
Allergy Concepts

Platinum

  • Bulla
  • NSW Food Authority
  • Mondelez
  • Novartis
  • Nutricia
  • Pfizer

Gold

  • dbv technologies
Silver
  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William
In Kind Supporters

  • CLAYTON UTZ
    EthiSEC
    Tonic Health Media
    ZOOM
    Impagination - Web Managers

Charity Status
Information Partner
Official Information Partner of Healthdirect Australia


© 2023 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 


ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.

ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.

I understand More information